1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D7E61B8D3B51F4B18525734E007630E8
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/structuring-pharmaceutical-market-analytics-to-support-product-growth?opendocument
18
19opendocument
2018.97.9.172
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Research, Analytics and Forecasting » Market Research Structure

Structuring Pharmaceutical Market Analytics to Support Product Growth

DB Image

ID: 4974


Features:

Metrics, Graphics, Summary Matrix


Pages/Slides: 25


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to sign-up for a complimentary tour of "Structuring Pharmaceutical Market Analytics to Support Product Growth"


STUDY OVERVIEW

In today’s highly competitive pharmaceutical industry, Market Analytics (see Key Definitions below) functions play a key role in charting a course that helps companies avoid pitfalls and increase profits. Leading companies build flexible, company-specific Market Analytics organizations and continuously evolve them to meet the changing needs of the portfolios and products they support. Executives who oversee Market Analytics organizations will be able to use this research document to understand the pros and cons of centralization, the benefits of various departmental alignments, the drivers of growth for analytics organizations and the organizational structures for analytics that are typical of companies as they grow and evolve the analytics function.

KEY TOPICS
· Executive Summary
· Structuring to Support Healthy Product Growth
· Centralization of Analytics Functions
· Activities Integration into Business Units
· Appendix A: Top Lessons Learned

KEY METRICS
· Organizational Structure Among Surveyed Companies
· Departmental Alignments for Analytics Activities
· Models of Analytics Organization Evolution, including Generalist, Differentiated, Specialist and Distributed

SAMPLE KEY FINDINGS
· There is no one-size-fits-all model for creating an effective Market Analytics structure. Rather, structure is highly specific to the product needs of each individual company. Winning companies drive high performance through closely aligning their analytics functions with the strategic marketing goals and lifecycle status of their brands.
· Pharma companies evolve their analytics functions continually as the profile of each product portfolio changes. Savvy companies reevaluate their needs and restructure Market Analytics functions to keep pace as key products move through their lifecycle.

STUDY METHODOLOGY
Best Practices, LLC completed this study in two phases — an online survey and telephone interviews. Researchers surveyed managers and executives from 21 leading pharmaceutical, medical device and biotechnology companies to collect benchmark metrics. Best Practices also used in-depth interviews with Market Analytics leaders at six selected companies to surface executive insights and winning practices they use to evolve the analytics functions and keep pace with company growth and change.

KEY DEFINITIONS
“Market Analytics” is used broadly to encompass a range of activities usually conducted in such departments as Market Research, Market Analytics, Business/ Commercial/Franchise/Brand Analytics, Business Development, Competitive/Business/Market Intelligence, Sales or Sales Operations, Pricing, Forecasting, Marketing, or Finance. This study focuses on individual analytics activities rather than on departments where they may or may not be performed; analytics functions are rarely all centralized in a single department.


Industries Profiled:
Pharmaceutical; Biotech; Health Care; Consumer Products


Companies Profiled:
Abbott Laboratories; Alcon; Amgen; Amylin; Aton Pharma; Boehringer Ingelheim; Cubist Pharmaceuticals; DSM Pharmaceutical; Eisai; Eli Lilly; Genzyme; Mead Johnson; Medrad; Novartis Canada; Ortho Biotech; Purdue Pharma; Sanofi-aventis; Sepracor; Shire; Vertex Pharmaceuticals; Xanodyne Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.